TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation

British Journal of Haematology
Jan M MiddekeStudy Alliance Leukaemia (SAL)

Abstract

Treatment success in patients with acute myeloid leukaemia (AML) is heterogeneous. Cytogenetic and molecular alterations are strong prognostic factors, which have been used to individualize treatment. Here, we studied the impact of TP53 mutations on the outcome of AML patients with adverse cytogenetic risk treated with allogeneic haematopoietic stem cell transplantation (HSCT). Samples of 97 patients with AML and adverse-risk cytogenetics who had received a HSCT within three randomized trials were analysed. Complete sequencing of the TP53 coding region was performed using next generation sequencing. The median age was 51 years. Overall, TP53 mutations were found in 40 patients (41%). With a median follow up of 67 months, the three-year probabilities of overall survival (OS) and event-free survival for patients with TP53 wild type were 33% [95% confidence interval (CI), 21% to 45%] and 24% (95% CI, 13% to 35%) compared to 10% (95% CI, 0% to 19%) and 8% (95% CI, 0% to 16%) (P = 0·002 and P = 0·007) for those with mutated TP53, respectively. In multivariate analysis, the TP53-mutation status had a negative impact on OS (Hazard Ratio = 1·7; P = 0·066). Mutational analysis of TP53 might be an important additional tool to predict out...Continue Reading

References

Mar 21, 2002·Nature Reviews. Cancer·T Soussi, C Béroud
Feb 5, 2003·Nature Genetics·Patrick DumontMaureen Murphy
Mar 25, 2006·Cell Death and Differentiation·J A Royds, B Iacopetta
Jan 20, 2009·Leukemia·H SeifertUNKNOWN Study Alliance Leukemia (SAL)
Jan 24, 2009·Nature Reviews. Cancer·Catherine WhibleyMonica Hollstein
May 25, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Markus SchaichGerhard Ehninger
Apr 17, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Nageswara Rao DunnaS Vishnupriya
Feb 26, 2013·British Journal of Haematology·Brigitte MohrUNKNOWN Study Alliance Leukaemia (SAL)
May 1, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Markus SchaichGerhard Ehninger
Aug 20, 2014·Annals of Hematology·Eduard SchulzHeinz Sill

❮ Previous
Next ❯

Citations

Aug 2, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marlise R LuskinRan Reshef
Jun 3, 2017·Leukemia & Lymphoma·Vijaya Raj BhattLori J Maness
Oct 12, 2017·Expert Opinion on Pharmacotherapy·Tracy Murphy, Karen W L Yee
Nov 3, 2017·Leukemia & Lymphoma·Shannon R McCurdy, Mark J Levis
Jan 11, 2020·Current Opinion in Hematology·Hannah Asghari, Chetasi Talati
Jan 9, 2020·Current Opinion in Hematology·Alexandra Gomez-Arteaga, Boglarka Gyurkocza
Dec 14, 2016·The New England Journal of Medicine·Elihu Estey
Feb 3, 2019·Cold Spring Harbor Molecular Case Studies·Mahesh SwaminathanCourtney D DiNardo
Dec 14, 2016·The New England Journal of Medicine·John S WelchTimothy J Ley
Mar 14, 2020·Cancers·Sayantanee DuttaHeinz Sill
Sep 8, 2020·Hematological Oncology·Zuzana SustkovaJiri Mayer
Aug 21, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Heinz SillDetlef Haase
Sep 24, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Bhagirathbhai DholariaArnon Nagler
Jan 19, 2020·Clinical Lymphoma, Myeloma & Leukemia·Prajwal DhakalVijaya Raj Bhatt
Aug 21, 2021·Frontiers in Immunology·Roberto LimongelloAntonio Pierini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cardiovascular Risk Prediction

Cardiovascular risk prediction models based on classical risk factors identified in epidemiological studies are useful in primary prevention of cardiovascular disease in individuals. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.